Adagene (ADAG) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Adagene Inc. showcased promising clinical data at the SITC meeting, highlighting the safety and efficacy of its novel anti-CTLA-4 therapy, ADG126, in combination with pembrolizumab for treating metastatic colorectal cancer. The therapy demonstrated enhanced therapeutic potential and safety profiles, offering hope for improved cancer treatment strategies. These findings underscore ADG126’s potential as a leading therapy in the immunotherapy landscape.
For further insights into ADAG stock, check out TipRanks’ Stock Analysis page.
